Among the features of the Part D structure is a federal reinsurance program in which, when a beneficiary reaches the catastrophic threshold in a given year, the government subsidizes 80% of remaining spending for the year. Part D plans pay 15%, and patients pay 5% in this scenario.
The rising cost of prescription drugs is an issue that impacts all American patients, and while a variety of policy proposals have been brought forward to address this issue—from the Trump administration’s proposal to link US drug prices with an international index to House Democrats’ proposals to allow Medicare to negotiate prices—a group of economists and policy experts have written a perspective article calling for changes to Part D that would see plans taking on greater risk.
Among the features of the Part D structure is a federal reinsurance program in which, when a beneficiary reaches the catastrophic threshold in a given year, the government subsidizes 80% of remaining spending for the year. Part D plans pay 15%, and patients pay 5% in this scenario.
According to the authors, in the first years of Part D, this reinsurance approach “seemed reasonable,” but the design has not kept pace with the market, particularly as specialty drugs have gained a prominent place in the healthcare landscape. Today, they write, reinsurance subsidies reach approximately $43 billion each year.
“As reinsurance spending grows disproportionately, plans bear less and less risk as a share of total spending,” say the authors. “This situation calls into question what is being gained through the use of private plans.”
Also of note is the fact that drug makers are largely responsible for contributions to address the Part D coverage gap, or “donut hole,” and plans have little liability for addressing costs in this phase. Federal policy that holds that Part D plans must cover nearly all drugs in 6 protected classes also limits plans’ ability to manage costs.
“The net result is that, today, Part D plans are actually responsible for only about 34% of total prescription-drug spending,” the authors write, while commercial plans paid an average of 85% of total drug costs in 2016.
The authors argue that Part D should be redesigned in order to relieve the disproportionate burden placed on the government and to make plans shoulder more risk. Any reforms should also include protections for beneficiaries, like out-of-pocket spending caps, and the government should be able to use its recouped funds to help keep premiums low.
“It took policymakers 40 years to add an outpatient prescription-drug benefit to the Medicare program. Let’s hope we don’t have to wait 40 more to modernize Part D,” write the authors.
Reference
Trish EE, Ginsburg PB, Joyce GF, Goldman DP. Who pays in Medicare Part D? Giving plans more skin in the game [published online November 20, 2019]. N Engl J Med. doi: 10.1056/NEJMp1912357.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.